Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series
Case Series
[키워드] Acute respiratory failure
Administered
administration
Admission
adverse effect
analyzed
Antibiotics
antibody
anticoagulation
antivirals
ARF
Bacterial infection
case sery
characterized
chronic
Comorbidity
COVID-19
COVID-19 patients
COVID-19 pneumonia
Critical
Critically ill
critically ill patients
develop
Dexamethasone
dosage
examined
had more
hallmark
hospital
hyperinflammation
ICU
infections
intensive care
interleukin-6 receptor
intravenous
intravenous infusion
male
measure
mechanical ventilation
mechanically ventilated
mechanically ventilated patient
monoclonal
Mortality
nine
nosocomial
not affect
not significant
outcome
overall mortality
oxygen support
Oxygen therapy
Patient
Physiology
Pneumonia
Prevalence
Prophylactic
receiving
Respiratory failure
retrospective
Safe
survival rate
therapy
Tocilizumab
tocilizumab therapy
Treatment
ventilated patient
were recorded
[DOI] 10.1016/j.amsu.2020.10.061 PMC 바로가기 [Article Type] Case Series
[DOI] 10.1016/j.amsu.2020.10.061 PMC 바로가기 [Article Type] Case Series